STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 203.55

Change

-1.05 (-0.51)%

Market Cap

USD 0.66B

Volume

698.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.01 (+0.03%)

USD 56.03B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-6.10 (-1.18%)

USD 13.60B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-4.80 (-1.29%)

USD 11.29B
WRD:PA HSBC MSCI World UCITS ETF

-0.34 (-0.99%)

USD 11.04B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-2.48 (-0.94%)

USD 10.45B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-8.00 (-1.74%)

USD 7.99B
WLD:PA Lyxor UCITS MSCI World D-EUR

-3.51 (-1.04%)

USD 7.49B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

-0.08 (-1.18%)

USD 7.42B
HHH:PA HSBC S&P 500 UCITS ETF

-0.62 (-1.18%)

USD 7.22B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

-0.57 (-0.70%)

USD 5.38B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.84% 29% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.84% 29% F 35% F
Trailing 12 Months  
Capital Gain -9.91% 6% D- 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.91% 6% D- 30% F
Trailing 5 Years  
Capital Gain 23.08% 28% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.08% 27% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain 9.06% 58% F 65% D
Dividend Return 9.06% 56% F 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.37% 73% C 88% B+
Risk Adjusted Return 108.21% 90% A- 94% A
Market Capitalization 0.66B 70% C- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike